Why the study?
What are the haemodynamic effects of labetalol in hypertensive subjects and patients with congestive heart failure?
What are the haemodynamic effects of labetalol in hypertensive subjects and patients with congestive heart failure?
Labetalol effectively lowers blood pressure in hypertension without reducing cardiac output, but may impair exercise hemodynamics in heart failure patients.
Answers are grounded in this paper and cite their sources.
Labetalol may compromise exercise hemodynamics in treated heart failure; leaves open prospective validation of its use in this population.
1 Labetalol at a dose of 800 to 1600 mg daily inhibited isoprenaline-induced tachycardia and phenylephrine-induced elevation in arterial pressure in hypertensive subjects. The beta-adrenoreceptor effect was four times more potent than the alpha-adrenoreceptor effect. 2 Isoprenaline-induced tachycardia was more effectively blocked than isoprenaline-induced inotropism, thereby raising the possibility of a subselective effect on cardiac beta-adrenoceptors. 3 Labetalol reduced blood pressure in hypertensive subjects with no change in cardiac output in the supine or upright position and with marked inhibition of the heart rate and blood pressure response to treadmill exercise. 4 Labetalol administered in single doses to patients with stable, treated congestive heart failure impaired blood pressure support during exercise. 5 The unique adrenoceptor and haemodynamic effects of labetalol make it a potentially attractive drug for management of hypertension and other cardiovascular disorders.
No takes yet. Share an insight, caveat, or question.
Cohn et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: